Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Sjaarda

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Diabetes Care|December 16, 2016
Growth Differentiation Factor 15 as a Novel Biomarker for MetforminHertzel C Gerstein, Guillaume Pare, Sibylle Hess, et al.
Clinical Chemistry|October 20, 2018
A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of DiseasePedrum Mohammadi-Shemirani, Jennifer Sjaarda, Hertzel C Gerstein, et al.
Molecular Psychiatry|May 12, 2023
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysisJennifer Sjaarda, Aurélie Delacrétaz, Céline Dubath, et al.
Translational Psychiatry|October 8, 2021
Correction: Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Translational Psychiatry|July 6, 2021
Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Frontiers in Psychiatry|January 6, 2022
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric CohortNermine Laaboub, Mehdi Gholam, Guibet Sibailly, et al.
Diabetes Care|September 29, 2018
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical TrialMario Luca Morieri, He Gao, Marie Pigeyre, et al.
Plos Medicine|February 3, 2022
Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysisJames Yarmolinsky, Virginia Díez-Obrero, Tom G Richardson, et al.
Diabetes|January 25, 2020
<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-LipidMario Luca Morieri, Hetal S Shah, Jennifer Sjaarda, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Diabetes Care|December 16, 2016
Growth Differentiation Factor 15 as a Novel Biomarker for MetforminHertzel C Gerstein, Guillaume Pare, Sibylle Hess, et al.
Clinical Chemistry|October 20, 2018
A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of DiseasePedrum Mohammadi-Shemirani, Jennifer Sjaarda, Hertzel C Gerstein, et al.
Molecular Psychiatry|May 12, 2023
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysisJennifer Sjaarda, Aurélie Delacrétaz, Céline Dubath, et al.
Translational Psychiatry|October 8, 2021
Correction: Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Translational Psychiatry|July 6, 2021
Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohortCéline Dubath, Mehdi Gholam-Rezaee, Jennifer Sjaarda, et al.
Frontiers in Psychiatry|January 6, 2022
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric CohortNermine Laaboub, Mehdi Gholam, Guibet Sibailly, et al.
Diabetes Care|September 29, 2018
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical TrialMario Luca Morieri, He Gao, Marie Pigeyre, et al.
Plos Medicine|February 3, 2022
Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysisJames Yarmolinsky, Virginia Díez-Obrero, Tom G Richardson, et al.
Diabetes|January 25, 2020
<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-LipidMario Luca Morieri, Hetal S Shah, Jennifer Sjaarda, et al.
Pageof 2